Qiagen has added new capabilities to the Qiagen Clinical Insight (QCI), its clinical decision support solution, which streamlines the annotation, interpretation and reporting of next-generation sequencing results for clinical laboratories.
Specifically, the company has expanded the solution to include support for leukemia and lymphoma testing as well as testing for hereditary cancers including breast and ovarian cancer, Lynch syndrome, Peutz-Jegher syndrome, ataxia telangiectasia, neurofibromatosis, hereditary diffuse gastric cancer, familial prostate cancer, polyposis, and many more. —This is in addition to existing support for analyzing somatic mutations in solid tumors. The updated software also offers new features for diagnostic testing as well as monitoring and progression, support for copy number variations and fusion genes, and additional prognostics data from the literature. It also provides comprehensive coverage of FDA- and EMA-approved drug labels, NCCN, ASCO and ESMO professional guidelines, and active genotype-related clinical trials.